Search details
1.
Patient preferences in the treatment of stage III/IV classic Hodgkin lymphoma: Results from the CONNECT cross-sectional survey.
Br J Haematol
; 204(4): 1262-1270, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38323849
2.
Physician frontline treatment preferences for stage III/IV classic Hodgkin lymphoma: the real-world US CONNECT study.
Future Oncol
; 20(12): 749-760, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-37665273
3.
Retrospective Analysis With Propensity Score Matching of Peripheral T-Cell Lymphoma Treated Frontline With Brentuximab Vedotin and Chemotherapy.
Oncologist
; 28(6): 520-530, 2023 06 02.
Article
in English
| MEDLINE | ID: mdl-36971492
4.
The impact of classic Hodgkin lymphoma on informal caregivers: results from the CONNECT cross-sectional survey.
Support Care Cancer
; 31(12): 664, 2023 Nov 02.
Article
in English
| MEDLINE | ID: mdl-37914825
5.
Phase 1 trial of carfilzomib in relapsed/refractory peripheral T-cell lymphoma.
Ann Hematol
; 101(2): 335-340, 2022 Feb.
Article
in English
| MEDLINE | ID: mdl-34668982
6.
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
Lancet
; 393(10168): 229-240, 2019 01 19.
Article
in English
| MEDLINE | ID: mdl-30522922
7.
Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation.
Blood
; 131(1): 84-94, 2018 01 04.
Article
in English
| MEDLINE | ID: mdl-29038339
8.
Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas.
Blood
; 131(19): 2120-2124, 2018 05 10.
Article
in English
| MEDLINE | ID: mdl-29507077
9.
Lenalidomide plus rituximab (R2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial.
Br J Haematol
; 185(5): 874-882, 2019 06.
Article
in English
| MEDLINE | ID: mdl-30919940
10.
Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma.
Br J Haematol
; 185(4): 670-678, 2019 05.
Article
in English
| MEDLINE | ID: mdl-30820940
11.
Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden.
Oncologist
; 24(2): 219-228, 2019 02.
Article
in English
| MEDLINE | ID: mdl-30108156
12.
Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma.
Blood
; 130(25): 2709-2717, 2017 12 21.
Article
in English
| MEDLINE | ID: mdl-28974506
13.
Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma.
Blood
; 130(4): 472-477, 2017 07 27.
Article
in English
| MEDLINE | ID: mdl-28522441
14.
Brentuximab vedotin with chemotherapy in adolescents and young adults with stage III or IV classical Hodgkin lymphoma in ECHELON-1.
Haematologica
; 109(3): 982-987, 2024 Mar 01.
Article
in English
| MEDLINE | ID: mdl-37794803
15.
Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin.
Hematol Oncol
; 37(1): 35-38, 2019 Feb.
Article
in English
| MEDLINE | ID: mdl-30209819
16.
Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ?
Ann Hematol
; 98(5): 1169-1176, 2019 May.
Article
in English
| MEDLINE | ID: mdl-30617643
17.
Prevalence of a Histologic Change of Ocular Adnexal Lymphoma in Patients With a History of Lymphoma.
Ophthalmic Plast Reconstr Surg
; 35(3): 243-246, 2019.
Article
in English
| MEDLINE | ID: mdl-30124609
18.
Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma.
Biol Blood Marrow Transplant
; 24(8): 1602-1609, 2018 08.
Article
in English
| MEDLINE | ID: mdl-29501779
19.
Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.
Cancer
; 124(12): 2561-2569, 2018 06 15.
Article
in English
| MEDLINE | ID: mdl-29723393
20.
Pre-treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma.
Br J Haematol
; 180(4): 545-549, 2018 02.
Article
in English
| MEDLINE | ID: mdl-29271057